Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer
全身递送靶向 TGFβ 的溶瘤腺病毒,以增强三阴性乳腺癌的抗 PD-1 和抗 CTLA-4 治疗
基本信息
- 批准号:10357928
- 负责人:
- 金额:$ 37.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:4T1AbraxaneAdenovirusesAmino AcidsAntibodiesAntibody titer measurementAntitumor ResponseAttenuatedBindingBiological AssayBiological MarkersBreast Cancer CellBreast Cancer ModelBreast Cancer PatientBreast Cancer TreatmentCTLA4 geneCell DeathCellsClinicalClinical TrialsCombination immunotherapyCombined Modality TherapyComplementarity Determining RegionsCytometryDevelopmentFDA approvedFiberFutureGenesGenetic TranscriptionGoalsHepaticHomingHumanImmuneImmune checkpoint inhibitorImmunoglobulin GImmunologicsImmunology procedureImmunosuppressive AgentsInflammatoryLiverLymphaticMalignant NeoplasmsMammary NeoplasmsMediatingMetastatic Neoplasm to the BoneModelingMusNeoplasm MetastasisNormal tissue morphologyOncogenesOncolytic virusesOsteolyticPaclitaxelPathway interactionsPatientsPeptidesPhenotypePopulationPrevalenceRNAResearchResistanceRoleSafetySignal PathwaySignal TransductionSpleenTGFB1 geneTechnologyTestingTherapy Clinical TrialsTherapy trialToxic effectTransforming Growth Factor betaTransforming Growth Factor beta ReceptorsTumor ImmunityViralVirusWomananti-CTLA-4 therapyanti-CTLA4anti-PD-1anti-PD-1/PD-L1anti-PD-L1anti-PD-L1 antibodiesanti-PD1 antibodiesanti-tumor immune responseantitumor agentbasebonecytokinegene panelimmune activationimmunogenicityimprovedin vivointerestmacrophagemolecular subtypesnano-stringneoplastic cellneutralizing antibodynovelnovel therapeuticsoncolytic adenovirusperipheral bloodprogrammed cell death ligand 1programmed cell death protein 1receptorresearch clinical testingresponsesubcutaneoussystemic toxicitytherapy resistanttranscriptometranscriptome sequencingtriple-negative invasive breast carcinomatumortumor growthtumor microenvironmenttumor specificityuptake
项目摘要
PROJECT SUMMARY
The development of novel therapies for the treatment of breast cancer is a major unmet need. In recent years,
immune checkpoint inhibitors including anti-PD-1, anti-PD-L1 and anti-CTLA-4 have shown promise as
antitumor agents, and are approved for the treatment of several malignancies. Clinical trials in breast cancer
patients have shown that about 20% of triple negative breast cancers (TNBC) respond favorably to anti-PD-1
antibodies and Atezolizumab, an anti-PD-L1 antibody in combination with
nab-paclitaxel (Abraxane)
is now
FDA approved for advanced stage TNBC patients with positive PDL-1 expression. However, many TNBC
patients are resistant to anti-PD-1/PDL-1 and anti-CTLA-4 treatments which could be due to weak
immunogenicity of the tumors and poor inflammatory but highly immune suppressive tumor microenvironment.
In recent years TGFβ has been shown to be a strong immune suppressor and can potentially produce a tumor
microenvironment that is resistant to anti-PD-1 and anti-CTLA-4 therapy. To overcome resistance to anti-PD-1
and anti-CTLA-4 we have developed adenoviruses (Ad) expressing sTGFβRIIFc (soluble TGFβ receptor II
fused with human IgG Fc). sTGFβRIIFc acts as a TGFβ decoy, and can inhibit TGFβ pathways. Initially, we
created Ad5 based Ad.sT expressing sTGFβRIIFc. To reduce hepatic/systemic toxicity associated with
systemic delivery of Ad.sT, we created mHAd.sT, a liver-detargeted virus, by replacing hypervariable regions
(HVRs) (1-7) of Ad.sT with Ad48 HVRs. To enhance tumor specificity, we have now created mHAdLyp.sT by
introducing LyP-1 peptide, a 9-amino acid long tumor homing-cell peptide, into the HI loop of the mHAd.sT
fiber. In this proposal, we will test the hypotheses that systemic administration of mHAdLyp.sT in mice bearing
4T1 triple negative mammary tumors will result in reduced hepatic/systemic toxicity but produce high levels of
sTGFβRIIFc and inhibit TGFβ pathways. This will alter the tumor microenvironment, induce tumor immunity,
and overcome resistance to anti-PD-1 and anti-CTLA-4., and examine the expression profiles of TGFβ-1,
TGFβ-1 regulated genes, and PD-1 and CTLA-4 signaling pathways. We will examine immuno-phenotypes in
tumors, peripheral blood and spleen (Aim 1). Next, we will examine mHAdLyp.sT, anti-PD-1 and anti-CTLA-4
combination therapies in mouse tumor models. We will conduct RNA-Seq analysis of the whole
transcriptomes, and examine the role of immune activation in mediating the anti-tumor responses (Aim 2). We
will test the hypothesis that systemic administration of mHLypAd.sT, in combination with anti-PD-1 and anti-
CTLA-4 in mice with pre-established metastases will be effective (Aim 3). To guide us for the combination
therapy trials with mHAdLyp.sT, anti-PD-1 and anti-CTLA-4, we will examine human TNBC tumors by
Nanostring technology for RNA profiling, and will further examine the TGFβ-1 and other relevant biomarkers
and TILS in human TNBC tumors. We will also screen the human population for the Ad neutralizing antibodies
titers (Aim 4). We believe that our research described here is critical to bring forward our oncolytic virus
mHAdLyp.sT targeting TGFβ in combination with anti-PD-1 and anti-CTLA-4 for clinical evaluation in TNBC
patients.
项目摘要
开发用于治疗乳腺癌的新疗法是一个主要的未满足的需求。近年来,
包括抗PD-1、抗PD-L1和抗CTLA-4在内的免疫检查点抑制剂已显示出作为
抗肿瘤剂,并且被批准用于治疗几种恶性肿瘤。乳腺癌临床试验
患者已经表明,约20%的三阴性乳腺癌(TNBC)对抗PD-1有良好的反应,
抗体和Atezolizumab,一种抗PD-L1抗体与
白蛋白结合型紫杉醇(Abraxane)
现在
FDA批准用于PDL-1表达阳性的晚期TNBC患者。然而,许多TNBC
患者对抗PD-1/PDL-1和抗CTLA-4治疗具有抗性,这可能是由于弱的
肿瘤的免疫原性和不良的炎性但高度免疫抑制的肿瘤微环境。
近年来,TGFβ已被证明是一种强免疫抑制剂,并可能产生肿瘤
在一些实施方案中,所述微环境对抗PD-1和抗CTLA-4疗法具有抗性。为了克服抗PD-1抗体的耐药性
和抗CTLA-4,我们已经开发了表达sTGFβRIIFc(可溶性TGFβ受体II)的腺病毒(Ad
与人IgG Fc融合)。sTGFβRIIFc作为TGFβ诱饵,可抑制TGFβ通路。最初我们
构建了表达sTGFβRIIFc的基于Ad 5的Ad.sT。为了减少与以下相关的肝脏/全身毒性:
系统性递送Ad.sT,我们通过替换高变区创建了mHAd.sT,一种肝脏去靶向病毒
(HVR)(1-7)的Ad.sT与Ad 48 HVR。为了增强肿瘤特异性,我们现在已经通过以下方式创建了mHAdLyp.sT:
将LyP-1肽(一种9个氨基酸长的肿瘤归巢细胞肽)引入mHAd的HI环中。
光纤在该提议中,我们将测试在携带mHAdLyp.sT的小鼠中全身施用mHAdLyp.sT的假设。
4 T1三阴性乳腺肿瘤将导致肝/全身毒性降低,但产生高水平的
sTGFβRIIFc和抑制TGFβ通路。这将改变肿瘤微环境,诱导肿瘤免疫,
并克服对抗PD-1和抗CTLA-4的耐药性,并检测TGFβ-1的表达谱,
TGFβ-1调节基因,PD-1和CTLA-4信号通路。我们将检查免疫表型,
肿瘤、外周血和脾脏(Aim 1)。接下来,我们将检查mHAdLyp.sT、抗PD-1和抗CTLA-4
在小鼠肿瘤模型中的联合疗法。我们将进行RNA-Seq分析,
转录组,并检查免疫活化在介导抗肿瘤应答中的作用(目的2)。我们
将检验mHLypAd.sT与抗PD-1和抗PD-2抗体的组合的全身给药的假设。
CTLA-4在具有预先建立的转移的小鼠中将是有效的(目的3)。来指导我们
在使用mHAdLyp.sT、抗PD-1和抗CTLA-4的治疗试验中,我们将通过以下方法检查人TNBC肿瘤:
Nanostring技术用于RNA分析,并将进一步检查TGFβ-1和其他相关生物标志物
和TILS。我们还将筛选人群中的Ad中和抗体
滴度(Aim 4)。我们相信,我们在这里描述的研究对于提出我们的溶瘤病毒至关重要。
靶向TGFβ的mHAdLyp.sT与抗PD-1和抗CTLA-4联合用于TNBC的临床评价
患者
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Weidong Xu其他文献
Weidong Xu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Weidong Xu', 18)}}的其他基金
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer
全身递送靶向 TGFβ 的溶瘤腺病毒,以增强三阴性乳腺癌的抗 PD-1 和抗 CTLA-4 治疗
- 批准号:
10117795 - 财政年份:2021
- 资助金额:
$ 37.44万 - 项目类别:
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer
全身递送靶向 TGFβ 的溶瘤腺病毒,以增强三阴性乳腺癌的抗 PD-1 和抗 CTLA-4 治疗
- 批准号:
10565945 - 财政年份:2021
- 资助金额:
$ 37.44万 - 项目类别:
Targeted Delivery of siRNA Nanoparticles to Prevent HIV-1 Transmission
靶向递送 siRNA 纳米颗粒以预防 HIV-1 传播
- 批准号:
7554936 - 财政年份:2008
- 资助金额:
$ 37.44万 - 项目类别:
相似海外基金
Transient tissue ‘priming’ via FAK inhibition to impair pancreatic cancer progression and improve sensitivity to gemcitabine/Abraxane
通过 FAK 抑制作用的瞬时组织“启动”可损害胰腺癌进展并提高对吉西他滨/Abraxane 的敏感性
- 批准号:
nhmrc : 1140125 - 财政年份:2018
- 资助金额:
$ 37.44万 - 项目类别:
Project Grants
Transient tissue ‘priming’ via FAK inhibition to impair pancreatic cancer progression and improve sensitivity to gemcitabine/Abraxane
通过 FAK 抑制作用的瞬时组织“启动”可损害胰腺癌进展并提高对吉西他滨/Abraxane 的敏感性
- 批准号:
nhmrc : GNT1140125 - 财政年份:2018
- 资助金额:
$ 37.44万 - 项目类别:
Project Grants
Single-cell optical window imaging in CDK1-FRET biosensor mice to assess tissue stiffness and optimise delivery and therapeutic response to Gemcitabine/Abraxane in pancreatic cancer.
CDK1-FRET 生物传感器小鼠的单细胞光学窗口成像可评估胰腺癌中的组织硬度并优化吉西他滨/Abraxane 的递送和治疗反应。
- 批准号:
nhmrc : GNT1105640 - 财政年份:2016
- 资助金额:
$ 37.44万 - 项目类别:
Project Grants
Single-cell optical window imaging in CDK1-FRET biosensor mice to assess tissue stiffness and optimise delivery and therapeutic response to Gemcitabine/Abraxane in pancreatic cancer.
CDK1-FRET 生物传感器小鼠的单细胞光学窗口成像可评估胰腺癌中的组织硬度并优化吉西他滨/Abraxane 的递送和治疗反应。
- 批准号:
nhmrc : 1105640 - 财政年份:2016
- 资助金额:
$ 37.44万 - 项目类别:
Project Grants
Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Brea
局部用咪喹莫特和每周 Abraxane 治疗 Brea 的 II 期研究
- 批准号:
8090410 - 财政年份:2009
- 资助金额:
$ 37.44万 - 项目类别:
Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Brea
局部用咪喹莫特和每周 Abraxane 治疗 Brea 的 II 期研究
- 批准号:
7631940 - 财政年份:2009
- 资助金额:
$ 37.44万 - 项目类别:
CLINICAL TRIAL: PHASE I TRIAL OF ABRAXANE IN COMBINATION WITH GEMCITABINE IN SOL
临床试验:ABRAXANE 与吉西他滨在 SOL 中联合使用的 I 期试验
- 批准号:
7716859 - 财政年份:2008
- 资助金额:
$ 37.44万 - 项目类别:
LCCC 0412: PHASE I CARBOPLATIN AND ABRAXANE IN PATIENTS WITH SOLID TUMORS
LCCC 0412:I 期卡铂和 ABRAXANE 用于实体瘤患者
- 批准号:
7625597 - 财政年份:2006
- 资助金额:
$ 37.44万 - 项目类别:
PHASE I TRIAL OF ABRAXANE IN COMBINATION WITH GEMCITABINE IN SOLID TUMORS
ABRAXANE 联合吉西他滨治疗实体瘤的 I 期试验
- 批准号:
7625658 - 财政年份:2006
- 资助金额:
$ 37.44万 - 项目类别:
LCCC 0412: PHASE I CARBOPLATIN AND ABRAXANE IN PATIENTS WITH SOLID TUMORS
LCCC 0412:I 期卡铂和 ABRAXANE 用于实体瘤患者
- 批准号:
7377549 - 财政年份:2005
- 资助金额:
$ 37.44万 - 项目类别: